Retrotrope is striving to change aging as we know it, so that people do not have to suffer the ravages of many degenerative diseases. Retrotope is a clinical stage pharmaceutical startup that is leading the advance of a revolutionary new unified theory of aging and degeneration that can result in dramatically new approaches to therapy. It is creating a new category of drugs composed of proprietary compounds that treat degenerative diseases and improve life as we age.

Retrotope is currently assessing technical proof of principle, regulatory requirements, and viability of several products in multiple market segments.

Retrotope has added Dr. Peter Milner to its Board of Directors in anticipation of its first-in-human clinical trial in the neurodegenerative disease, Friedreich’s ataxia. 

Lipid peroxidation is essential for α-synuclein-induced cell death. (Journal of Neurochemistry. March 1, 2015)